
	Where results make sense

Topic: Apotex

	Apotex Inc - CorporateInformation
		Apotex Inc. was founded in 1974, and is the largest Canadian-owned pharmaceutical company.
		Apotex produces more than 260 generic pharmaceuticals in over 4000 dosages and formats which, in Canada, are used to fill over 60 million prescriptions a year - the largest amount of any pharmaceutical company in this country.
		Apotex has also established a presence through subsidiaries, joint ventures or licensing agreements in the Czech Republic, Mexico, China, Poland, New Zealand, France, Italy and Russia, to name just a few.
	www.apotex.com /CorporateInformation/Default.asp (321 words)

	Apotex Inc - Sales
		While Apotex is at the forefront of drug-related research, we’re also leading the way in finding superior methods of manufacturing, testing, packaging and distribution of quality medicines.
		Apotex has recently expanded its facilities, and now relies on new, state of the art installations that allow us to manufacture and package medicines in Canada, Mexico and in other parts of the world, helping to satisfy the global demand for affordable quality medicines.
		Apotex believes that a strong and innovative pharmaceutical company is vital for health in all parts of the world.
	www.apotex.com /Sales/Manufacturing.asp (530 words)

	Bristol-Myers' shares sink after rival drug launch (Site not responding. Last check: 2007-11-01)
		Apotex's announcement Tuesday that it had begun selling the drug came just hours after Bristol-Myers disclosed it was expecting such a move in an SEC filing.
		Apotex reiterated in a statement Tuesday that its version of Plavix doesn't infringe on the drug patent because the patent is invalid.
		Apotex is a privately held company that has a reputation for aggressively challenging patents.
	www.mercurynews.com /mld/mercurynews/business/15232049.htm?template=contentModules/printstory.jsp (466 words)

	Apotex Inc - PressReleases
		The ruling is a major step forward toward launch of Apotex’s generic version of GSK’s Paxil® as the decision is subject to appeal and other patents remain to be litigated.
		Apotex has already secured summary judgment that the ‘944 and ‘233 product claims are invalid, and has asked Judge Surrick to order GSK to de-list these two patents to permit FDA to issue final approval.
		Apotex Corp. is a wholly owned subsidiary of Apotex Inc., a 26 year old privately held company with headquarters in Toronto, Canada.
	www.apotex.com /PressReleases/20030304-01.asp (539 words)

	Apotex Inc - PressReleases
		Apotex Inc. is expanding operations at its many facilities (including Novex Pharma and TorPharm) and is hiring for positions in the Operations, Biomedical, Quality and Research and Development divisions.
		Apotex produces more than 180 generic pharmaceuticals in over 450 dosages, which, in Canada, are used to fill over 42 million prescriptions a year.
		Apotex is in the top 15 research and development companies in Canada and plans to spend $1 billion in research and development over the next 10 years.
	www.apotex.com /PressReleases/20011212-01.asp (397 words)

	Apotex Inc - PressReleases
		Apotex Chief Executive Officer Dr. Barry Sherman said: "Apotex believes its clopidogrel launch to be the largest and most successful launch in the history of the generic industry.
		At the time of the ANDA's approval, Apotex was in the midst of patent litigation with Sanofi-Aventis concerning clopidogrel in the U.S. District Court of the Southern District of New York, over the validity and enforceability the '265 patent.
		Apotex' clopidogrel tablets are packaged in bottles of 30s, 90s, 1000s, and 100 count unit dose blisters.
	www.apotex.com /PressReleases/20060808-01.asp?Printer=yes&xmlfile= (681 words)

	Apotex Inc.
		Apotex Inc. is a large Canadian pharmaceutical company employing 6,000 individuals worldwide in the fields of research, development, manufacturing and distribution.
		Apotex is aware that skilled immigrants might face communication issues that affect their ability to succeed and excel in the workforce.
		Apotex funds this course because it believes there is a return on investment in developing an efficient and skilled workforce.
	www.hireimmigrants.ca /apotex_d.htm (337 words)

	Apotex Receives Approval for First Generic Plavix® (Site not responding. Last check: 2007-11-01)
		Apotex is currently involved in patent litigation with Sanofi - Aventis over the validity and enforceability of U.S. Patent No. 4,847,265 pending in U.S. District Court of the Southern District of New York.
		Apotex was the first generic to file with the FDA, and thus is entitled to 180-days of generic market exclusivity.
		Apotex Chief Executive Officer Dr. Barry Sherman said: “Apotex is confident that the patent will be held invalid and that an affordable generic alternative to Plavix® will be available to consumers.
	www.apotex.ca /En/AboutApotex/PressReleases/20060125-01.asp (290 words)

	Apotex Inc - PressReleases
		Dr. Michael Spino, Senior Vice-President, Scientific Affairs, at Apotex stated that: “This donation will prove useful in training more associate clinicians, and, indirectly, more students, thus helping the present shortage of qualified pharmacists in Quebec.” Concluded Dr. Spino, “This donation is one in a series made to various universities.
		In recognition of this generous contribution, the Faculty of Pharmacy will use Apotex’s name for one of the rooms in the new Jean Coutu Pavilion that will be used to train associate clinicians.
		The mission of the Université de Montréal’s Faculty of Pharmacy involves training pharmacists so that they are able to provide pharmaceutical care to their communities, contributing research to advance knowledge of medications and their indications, training researchers and sources specialized in the area of pharmaceuticals, and sharing expertise with diverse national and international groups.
	www.apotex.com /PressReleases/20021204-01.asp (571 words)

	DeltaV Success Stories \| Apotex
		The Apotex company, a manufacturer of pharmaceutical products, had a need to increase capacity on its plant's effluent processing, as well as to manage a wide variety of effluent treatment requirements.
		Key elements of the application are two master sequential function charts (SFCs) which control the sequencing of the two effluent tanks, and a pH control strategy used to clean the effluent to the appropriate level.
		From Apotex' standpoint, the most significant discovery using the DeltaV system was how easy it is to learn and use by the plant operators.
	www.easydeltav.com /successstories/apotex.asp (312 words)

	TheStar.com - Profit hit by heart drug copies
		Apotex, meanwhile, scurried yesterday to ask the court to postpone enforcement of its ruling until Apotex has a chance to appeal.
		Apotex also argued that a $400 million (U.S.) bond the U.S. court required Bristol-Myers to post was "grossly inadequate." The bond is security for Apotex in case the court decides the injunction was wrongly imposed.
		When Apotex launched its version on Aug. 8, it was looking to take advantage of a 180-day window in which it would be the only company allowed to sell a generic copy of the heart medicine.
	www.thestar.com /NASApp/cs/ContentServer?pagename=thestar/Layout/Article_PrintFriendly&c=Article&cid=1157147419226&call_pageid=970599119419 (559 words)

	Apotex Inc - PressReleases
		“Apotex’s unprecedented investment of $627 million is a testament to our commitment to Canada and to global healthcare needs,” said Jack Kay, President and COO of Apotex.
		Apotex now employs more than 6,000 people worldwide and is one of the top fifteen employers in Ontario.
		Apotex produces more than 240 generic pharmaceuticals in approximately 4000 dosages and formats which, in Canada, are used to fill over 55 million prescriptions a year - the largest amount of any pharmaceutical company in this country.
	www.apotex.com /PressReleases/20041109-01.asp (483 words)

	Apotex Inc - PressReleases
		The Apotex Group has 4,300 employees including over 1,800 scientific staff and is fully integrated with an RandD budget of $1 billion expenditures over the next 10 years.
		It exports 210 medicines to 115 countries and construction is underway to expand the Canadian facilities to meet the world demand for quality generic medicines.
		Apotex prides itself on being the number one people organization in the pharmaceutical industry in Canada.
	www.apotex.com /PressReleases/20020612-01.asp (238 words)

	Globeinvestor.com: Bristol, Apotex mum on Medco's generic Plavix view (Site not responding. Last check: 2007-11-01)
		Privately held Apotex is the only drugmaker to have won final U.S. marketing approval for a generic form of Bristol-Myers Squibb's Plavix, the world's second- biggest-selling drug, which accounts for 30 percent of Bristol's profit.
		Although Apotex is already approved to launch its generic, it has not done so due to an ongoing patent battle with Bristol over the drug.
		That is because under federal law, when a drug maker launches a generic that is later found to have infringed the branded drug's patent, it can be forced to pay the original drug maker three times the sales lost due to the generic rival.
	www.globeinvestor.com /servlet/ArticleNews/print/ROC/20060804/2006-08-04T150451Z_01_N04174173_RTRIDST_0_BUSINESS-BRISTOLMYERS-APOTEX-COL (248 words)

	Apotex Inc - CorporateInformation
		Apotex’s first innovative drug Ferriprox™ was approved in Europe for use in the treatment of Thalassemia patients.
		Apotex is also very active in the growing area of biotechnology through publicly traded (TSE) Cangene Inc. It has approvals around the world for the innovative product WinRho SDF, a second generation hyper immune globulin.
		R and D expenditures for Apotex in 2005 was $153 million representing close to 20.6% of sales, placing Apotex in the top 15 research and development companies in Canada and the top pharmaceutical company.
	www.apotex.com /CorporateInformation/LeadingTheWay.asp?Printer=yes&xmlfile= (326 words)

	TheStar.com - Apotex unveils generic blood thinner
		Apotex conducted research and development at the company's Brantford facility and workers in the firm's Toronto operation manufactured the drug.
		Apotex's drug was approved by the U.S. Food and Drug Administration in January but will be considered "at risk" because "the patent situation as to whether or not we're infringing has yet to be decided upon," Kay said.
		Apotex, founded in 1974, says it is the largest Canadian-owned pharmaceutical company after growing to more than 6,000 employees in research, development, manufacturing and distribution facilities worldwide.
	www.thestar.com /NASApp/cs/ContentServer?pagename=thestar/Layout/Article_PrintFriendly&c=Article&cid=1155073815121 (771 words)

	Digital Rain - Portfolio Apotex
		Apotex required a verifiable way to both establish an active contact resource of graduating students that are interested in a pharmaceutical career but also to convey information and interest from Apotex to those students, at an East Coast Career Fair.
		Apotex was able to poll needs and desires of a future employable resources thereby not only providing information to HR but also to understand the needs and hopes of these potential employees.
		Apotex supports an active continuing education environment and will utilize the information collected to better service that mandate.
	www.digitalrain.com /portfolio_apotex.htm (233 words)

	Apotex Inc - PressReleases
		With an Apotex work force from over 80 different countries, including many directly impacted, “it was the right thing for us to help out”, concluded Mr.
		The privately-owned Canadian Apotex Group is one of the largest generic pharmaceutical companies in the world, manufacturing more than 240 affordable medicines for export to 115 countries.
		The Apotex Group is planning to invest more than $1 billion in research and development over the next 10 years.
	www.apotex.com /PressReleases/20050105-01.asp (212 words)

	Apotex Inc - PressReleases
		— The Apotex Group of Companies announced today that it is prepared to produce a key HIV/AIDS drug under legislation introduced yesterday to allow Canadian-made generic pharmaceuticals to be exported to developing countries in times of health crises.
		Apotex could manufacture Apo-Zidovidine, a generic equivalent of Retrovir-AZTÒ, to help combat HIV/AIDS in developing countries, in Canada using raw materials made in our fine chemical plant in Brantford, Ontario.
		The Canadian-owned Apotex Group is one of the largest generic pharmaceutical companies in the world manufacturing more than 220 affordable medicines for export to 115 countries.
	www.apotex.com /PressReleases/20031107-01.asp?Printer=yes&xmlfile= (254 words)

	Apotex Inc - PressReleases
		WINNIPEG, MANITOBA – Apotex Inc. has pledged $3 million to assist the Faculty of Pharmacy create a new teaching and research facility on the University of Manitoba's Bannatyne campus.
		The Apotex Group has 5,300 employees in 21 facilities in Ontario and Manitoba.
		Apotex Group is the largest research and development spender in Manitoba and first across Canada in the pharmaceutical industry.
	www.apotex.com /PressReleases/20050221-01.asp?Printer=yes&xmlfile= (360 words)

	Apotex Inc - PressReleases
		Apotex was the first drug manufacturer to challenge the validity of patents covering Paxil® and the first to gain FDA approval and bring a low-cost Paxil® alternative to consumers.
		Apotex Corp. is the U.S. subsidiary of Apotex Inc., the largest Canadian-owned manufacturer of prescription drugs in Canada.
		Apotex manufactured generic pharmaceuticals are sold in 115 countries around the world.
	www.apotex.com /PressReleases/20030908-01.asp (322 words)

	Apotex Inc - PressReleases
		In November of 2004, Apotex had announced the completion of a $624 million expansion of four different facilities, the largest in Canadian history.
		The Etobicoke building was a key component of this expansion and provides Canada the capacity to provide quality generic medicines to the world healthcare market.
		Apotex is this country’s largest Canadian-owned pharmaceutical company, headquartered in Ontario with 5,300 employees and 21 facilities.
	www.apotex.com /PressReleases/20050314-01.asp (293 words)

	Apotex Inc - PressReleases
		Apotex Corp. today announced it has received an Approvable Letter from the U.S. Food and Drug Administration (FDA) for its gabapentin capsules.
		Apotex products are used by millions of patients around the world each year.
		Apotex currently leads the industry in new generic FDA approvals for 2002.
	www.apotex.com /PressReleases/20021209-01.asp (264 words)

	Apotex Inc - SiteTerms.asp
		Apotex makes no representation and disclaims all express and implied warranties and conditions, including, but not limited to, accuracy, timeliness, completeness, non-infringement, or fitness for any purpose, and Apotex assumes no responsibility to any viewer or third party for the consequences of any errors or omissions.
		Apotex Inc. cannot and does not warrant the accurary, completeness, timeliness, non-infringement or fitness for a particular purpose of any information available through these links and disclaims any opinions expressed on such sites.
		Apotex’s inclusion of these links does not signify Apotex’s endorsement of the sites or the information contained therein, and is in no way a suggestion that the information available through these sites is appropriate for your particular circumstances.
	www.apotex.com /SiteTerms.asp?Printer=yes&xmlfile= (308 words)

	[No title]
		Apotex's '118 patent was directed to a process for preparing amorphous cefuroxime axetil.
		While Apotex was merely rewriting a dependent claim into independent form, the effect on the subject matter was substantial.
		Because acetic acid was a foreseeable equivalent to formic acid that could have and should have been included in the original claim, and acetic acid and acetone (acknowledged prior art) were similar in polarity, the court concluded that Apotex had not overcome the presumption that it surrendered coverage of acetic acid.
	www.aplf.org /mailer/issue139.html (390 words)

	Apotex Inc - Sales
		Apotex International is the worldwide sales and marketing division of Apotex Inc. for products sold outside of Canada and the United States.
		Representing the largest Canadian -owned pharmaceutical Company, Apotex International has established working relationships in more than 115 countries worldwide through a commitment to manufacturing excellence, and a first to market product development strategy for bio-equivalent generics.
		Through an ever expanding network of wholly owned subsidiaries, distributor and contract supply agreements, Apotex International is poised to take it’s place amongst the world’s leading bio-equivalent generic companies.
	www.apotex.com /Sales/InternationalSales.asp (87 words)

	Knobbe Martens Olson & Bear LLP - IP Litigation, Ranbaxy Pharmaceuticals, Inc. and Ranbaxy Laboratories Limited v. ...
		Apotex, Inc. [02-CV-848 (D. In a declaratory judgement action, the firm successfully defended Ranbaxy Pharmaceuticals, Inc. and Ranbaxy Laboratories Limited, one of the world’s largest generic pharmaceutical companies, against patent infringement counter claims brought by Apotex, Inc., a competing generic pharmaceutical company.
		Apotex alleged that Ranbaxy’s process for producing cefuroxime axetil, an anti-infective drug, infringed Apotex’s process patent.
		Apotex first sought a temporary restraining order and later a preliminary injunction preventing Ranbaxy from importing and selling its drug.
	www.kmob.com /prac_iplitigation_ranbaxy.htm (273 words)

Try your search on: Qwika (all wikis)